Consistent with this hypothesis, in a recent meta-analysis of cetuximab clinical trial data, De Roock et al (2010) clearly demonstrated that patients with colorectal tumours with a G13D mutation were significantly more likely to respond to cetuximab treatment than other K-Ras mutant tumours and survived longer. The gene discussed is KRAS; the disease is colorectal neoplasm.